BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

66.68 -0.57 (-0.85%)

Delayed Quote Updated: 12:46 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BridgeBio Pharma, Inc. - Common Stock

< Previous 1 2

...

9 10 11 12 13 14 15 16 Next >

Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023 ↗

October 24, 2023

Via Benzinga

The Latest Analyst Ratings for BridgeBio Pharma ↗

October 24, 2023

Via Benzinga

BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 11, 2023

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma Inc. (NASDAQ: BBIO) is a Stock Spotlight on 8/18

August 18, 2023

Via Investor Brand Network

BridgeBio Pharma Announces New England Journal of Medicine Publication of Positive Encaleret Proof-of-Concept Phase 2b Results in Patients with Autosomal Dominant Hypocalcemia Type 1 (ADH1)

October 10, 2023

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma Shares Positive Long-Term Data from an Ongoing Phase 2 Study, which Support the Potential Use of Glycosylated Alpha-dystroglycan (⍺DG) Levels as a Surrogate Endpoint in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

October 09, 2023

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio and Resilience Announce Strategic Multi-Year Partnership to Advance BBP-631, BBP-812 and Future Gene Therapy Treatments

October 03, 2023

From National Resilience, Inc.

Via Business Wire

4 Analysts Have This to Say About BridgeBio Pharma ↗

August 14, 2023

Via Benzinga

Expert Ratings for BridgeBio Pharma ↗

July 18, 2023

Via Benzinga

BridgeBio and Resilience Announce Strategic Multi-Year Partnership to Advance BBP-631, BBP-812 and Future Gene Therapy Treatments

October 03, 2023

From BridgeBio Pharma, Inc.

Via GlobeNewswire

Impact on BioMarin's Sentiment: Voxzogo's Triumph Clouded by Uncertainty ↗

September 28, 2023

Raymond James initiated coverage on BioMarin Pharmaceuticals Inc (NASDAQ: BMRN) with a Market Perform rating, noting sparsity in

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 28, 2023

Via Benzinga

BridgeBio Pharma Announces $250 Million Private Placement Equity Financing

September 25, 2023

From BridgeBio Pharma, Inc.

Via GlobeNewswire

Buy List Alert: 3 Pharma Stocks with Positive Trial Updates ↗

September 13, 2023

These three pharma stocks could be driven higher amidst future revenue prospects as they report to investors positive clinical developments.

Via InvestorPlace

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

September 08, 2023

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

September 07, 2023

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma Announces Positive Feedback from the U.S. FDA and EU EMA on the Regulatory Path for a Pivotal Phase 3 Trial of Infigratinib in Children with Achondroplasia

September 06, 2023

From BridgeBio Pharma, Inc.

Via GlobeNewswire

What's Going On With BridgeBio Pharma Stock Today? ↗

August 28, 2023

BridgeBio Pharma Inc (NASDAQ: BBIO) announced the presentation of detailed results from its Phase 3 ATTRibute-CM study of acoramidis for ATTR-CM at the

Via Benzinga

Pfizer Was First In Treating This Heart Disease. Why BridgeBio Could Be Better. ↗

August 28, 2023

The companies are expected to compete in a genetic heart disease beginning in late 2024.

Via Investor's Business Daily

BridgeBio presents detailed positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) at European Society of Cardiology Congress 2023

August 27, 2023

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma to Present Detailed Results from the Phase 3 ATTRibute Study in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) at European Society of Cardiology (ESC) Congress 2023

August 24, 2023

From BridgeBio Pharma, Inc.

Via GlobeNewswire

Wall Street Thinks BridgeBio Pharma Could Rise Over 40% -- But Will It? ↗

August 09, 2023

Its potential upcoming drug launch might not be enough.

Via The Motley Fool

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

August 04, 2023

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma Reports Second Quarter 2023 Financial Results and Business Update

August 03, 2023

From BridgeBio Pharma, Inc.

Via GlobeNewswire

7 A-Rated Stocks for Your August Buy List ↗

August 03, 2023

August is shaping up to be a great month for the stock market. Now you just need to make sure you own these A-rated stocks.

Via InvestorPlace

BridgeBio Pharma Announces Opportunity for Accelerated Approval Pathway in Limb-girdle Muscular Dystrophy Type 2I (LGMD2I/R9) Based on Glycosylated Alpha-dystroglycan (⍺DG) Levels and Announces First Patient Dosed in FORTIFY Phase 3 Study

July 31, 2023

From BridgeBio Pharma, Inc.

Via GlobeNewswire

Could This Stock Be the Next Biotech Buyout? ↗

July 31, 2023

A buyout deal recently pushed Reata Pharmaceuticals stock 53% higher in a single trading session, leading investors to wonder who's next.

Via The Motley Fool

Why Shares of BridgeBio Pharma Skyrocketed This Week ↗

July 21, 2023

The biotech company saw strong results in a phase 3 trial.

Via The Motley Fool

Dow Jones Leads Market Advance As Tesla, Netflix, Taiwan Semiconductor Hit Growth: Weekly Review ↗

July 21, 2023

But all the major indexes are at or near 15-month highs.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For July 18, 2023 ↗

July 18, 2023

Via Benzinga

< Previous 1 2

...

9 10 11 12 13 14 15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.